Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma

We conducted a phase II study of the AKT inhibitor, MK2206 in patients with relapsed or refractory lymphoma of any histology excluding Burkitt lymphoma or lymphoblastic lymphoma. MK-2206 was administered orally at 200 mg once weekly in 28-d cycles up to 12 cycles in the absence of progression or sig...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Br J Haematol
Autori principali: Oki, Yasuhiro, Fanale, Michelle, Romaguera, Jorge, Fayad, Luis, Fowler, Nathan, Copeland, Amanda, Samaniego, Felipe, Kwak, Larry W., Neelapu, Sattva, Wang, Michael, Feng, Lei, Younes, Anas
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2015
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5278973/
https://ncbi.nlm.nih.gov/pubmed/26213141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13603
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi